NASDAQ:REPL

Replimune Group (REPL) Stock Forecast, Price & News

$22.95

+3.96 (+20.85%)

(As of 01:45 PM ET)

Compare

Today's Range: $20.01
▼
$23.13
50-Day Range: $15.65
▼
$19.70
52-Week Range: $13.84
▼
$29.52

Volume: 699,734 shs
Average Volume: 542,740 shs
Market Capitalization: $1.33 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $51.60

Replimune Group MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 151.3% Upside
$51.80 Price Target
Short Interest: Bearish
17.04% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.28
Upright™ Environmental Score
News Sentiment: 0.49
Based on 11 Articles This Week
Insider Trading: Selling Shares
$1 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.57) to ($3.96) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

358th out of 980 stocks

Biological Products, Except Diagnostic Industry

53rd out of 163 stocks

3.5

Analyst's Opinion

Consensus Rating
Replimune Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $51.80, Replimune Group has a forecasted upside of 151.3% from its current price of $20.61.
Amount of Analyst Coverage
Replimune Group has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
17.04% of the float of Replimune Group has been sold short.
Short Interest Ratio / Days to Cover
Replimune Group has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Replimune Group has recently increased by 2.75%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Replimune Group does not currently pay a dividend.
Dividend Growth
Replimune Group does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Replimune Group has received a 69.41% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" product. See details.
Environmental Sustainability
The Environmental Impact score for Replimune Group is -1.28.

2.5

News and Social Media Coverage

News Sentiment
Replimune Group has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Replimune Group this week, compared to 2 articles on an average week.
MarketBeat Follows
3 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,003,634.00 in company stock.
Percentage Held by Insiders
23.80% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
87.83% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Replimune Group are expected to decrease in the coming year, from ($3.57) to ($3.96) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Replimune Group is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Replimune Group is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Replimune Group has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Stock News Headlines

June 5, 2023 | americanbankingnews.com

Replimune Group (NASDAQ:REPL) Shares Gap Up on Analyst Upgrade

June 5, 2023 | americanbankingnews.com

Replimune Group (NASDAQ:REPL) Shares Gap Up Following Analyst Upgrade

June 5, 2023 | Edge On The Street (Ad)

New "Mined in America" Lithium Opportunities?

The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.

June 5, 2023 | markets.businessinsider.com

EF Hutton Remains a Buy on Replimune Group (REPL)

June 5, 2023 | finance.yahoo.com

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors

June 5, 2023 | americanbankingnews.com

HC Wainwright Increases Replimune Group (NASDAQ:REPL) Price Target to $51.00

June 3, 2023 | tmcnet.com

Replimune Presents RP1 Data from the IGNYTE anti-…

June 3, 2023 | finance.yahoo.com

Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

June 5, 2023 | Edge On The Street (Ad)

New "Mined in America" Lithium Opportunities?

The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.

June 1, 2023 | finance.yahoo.com

Replimune to Present at the Jefferies Global Healthcare Conference

May 29, 2023 | markets.businessinsider.com

SVB Securities Reaffirms Their Buy Rating on Replimune Group (REPL)

May 26, 2023 | msn.com

EF Hutton Reiterates Replimune Group (REPL) Buy Recommendation

May 26, 2023 | americanbankingnews.com

FY2024 EPS Estimates for Replimune Group, Inc. (NASDAQ:REPL) Cut by Wedbush

May 25, 2023 | finance.yahoo.com

Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023 | americanbankingnews.com

Replimune Group, Inc. (NASDAQ:REPL) Expected to Earn Q1 2024 Earnings of ($0.87) Per Share

May 23, 2023 | markets.businessinsider.com

BMO Capital Keeps Their Buy Rating on Replimune Group (REPL)

May 22, 2023 | msn.com

Wedbush Reiterates Replimune Group (REPL) Outperform Recommendation

May 22, 2023 | americanbankingnews.com

Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Recommendation of "Buy" by Analysts

May 20, 2023 | americanbankingnews.com

Jean M. Franchi Sells 11,351 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

May 20, 2023 | americanbankingnews.com

Replimune Group, Inc. (NASDAQ:REPL) CEO Philip Astley-Sparke Sells 17,902 Shares

May 18, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Teva Pharmaceutical (TEVA) and Replimune Group (REPL)

May 18, 2023 | marketwatch.com

Replimune Group Chief Financial Officer Jean Franchi Resigns >REPL

May 18, 2023 | msn.com

Recap: Replimune Group Q4 Earnings

May 18, 2023 | finance.yahoo.com

Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update

May 17, 2023 | finance.yahoo.com

Is a Surprise Coming for Replimune (REPL) This Earnings Season?

May 9, 2023 | finance.yahoo.com

Replimune to Participate in the Piper Sandler Spring Biopharma Symposium

April 25, 2023 | americanbankingnews.com

Replimune Group, Inc. (NASDAQ:REPL) Receives $51.67 Average Price Target from Brokerages

See More Headlines

REPL Price History

30 days | 90 days | 365 days | Advanced Chart

REPL Company Calendar

Last Earnings: 11/04/2021
Today: 6/05/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:REPL
CUSIP: N/A
CIK: 1737953
Web: www.replimune.com
Phone: (781) 222-9600
Fax: N/A
Employees: 152
Year Founded: 2015

Price Target and Rating

Average Stock Price Forecast: $51.60
High Stock Price Forecast: $70.00
Low Stock Price Forecast: $34.00
Forecasted Upside/Downside: +171.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-174,280,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -35.84%
Return on Assets: -31.39%

Debt

Debt-to-Equity Ratio: 0.09
Current Ratio: 17.52
Quick Ratio: 17.52

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.61 per share
Price / Book: 1.98

Miscellaneous

Outstanding Shares: 57,780,000
Free Float: 44,025,000
Market Cap: $1.10 billion
Optionable: Not Optionable
Beta: 1.64

Key Executives

Philip Astley-Sparke
Chief Executive Officer & Director

Robert Coffin
President & Director

Colin A. Love
Chief Operating Officer

Jean M. Franchi
Chief Financial Officer, Secretary & Treasurer

Konstantinos Xynos
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

REPL Stock - Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" REPL shares.
View REPL analyst ratings or view top-rated stocks.
What is Replimune Group's stock price forecast for 2023?: 5 Wall Street analysts have issued 12-month target prices for Replimune Group's shares. Their REPL share price forecasts range from $34.00 to $70.00. On average, they expect the company's stock price to reach $51.60 in the next year. This suggests a possible upside of 171.7% from the stock's current price.
View analysts price targets for REPL or view top-rated stocks among Wall Street analysts.
How have REPL shares performed in 2023?: Replimune Group's stock was trading at $27.20 at the start of the year. Since then, REPL shares have decreased by 30.2% and is now trading at $18.99.
View the best growth stocks for 2023 here.
When is Replimune Group's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our REPL earnings forecast.
How were Replimune Group's earnings last quarter?: Replimune Group, Inc. (NASDAQ:REPL) issued its earnings results on Thursday, November, 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.05.
What ETFs hold Replimune Group's stock?: ETFs with the largest weight of Replimune Group (NASDAQ:REPL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Loncar Cancer Immunotherapy ETF (CNCR), Horizon Kinetics Medical ETF (MEDX), ALPS Medical Breakthroughs ETF (SBIO), First Trust Innovation Leaders ETF (ILDR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).
What other stocks do shareholders of Replimune Group own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?: (REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.
What is Replimune Group's stock symbol?: Replimune Group trades on the NASDAQ under the ticker symbol "REPL."
Who are Replimune Group's major shareholders?: Replimune Group's stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (9.70%), BlackRock Inc. (6.39%), State Street Corp (5.13%), BVF Inc. IL (3.78%), FMR LLC (2.04%) and Dimensional Fund Advisors LP (1.90%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke, Robert Coffin and Sushil Patel.
View institutional ownership trends.
How do I buy shares of Replimune Group?: Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Replimune Group's stock price today?: One share of REPL stock can currently be purchased for approximately $18.99.
How much money does Replimune Group make?: Replimune Group (NASDAQ:REPL) has a market capitalization of $1.10 billion. The company earns $-174,280,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.
How many employees does Replimune Group have?: The company employs 152 workers across the globe.
How can I contact Replimune Group?: Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com.

This page (NASDAQ:REPL) was last updated on 6/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Replimune Group (REPL) Stock Forecast, Price & News

Replimune Group MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Replimune Group (NASDAQ:REPL) Stock

REPL Stock News Headlines

REPL Price History

REPL Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

REPL Stock - Frequently Asked Questions

Overall MarketRank^™